Speciality: Nephrology
Description:
A warm welcome to all the medical professionals in this interesting session on Evidence to Practice: State of the art CKD Care with SLGT2- inhibitors use of SGLT2 inhibitors represents a groundbreaking advance in the management of chronic kidney disease (CKD), supported by robust clinical evidence. These agents, originally developed for glycemic control in diabetes, have demonstrated significant renoprotective effects, including slowing CKD progression, reducing albuminuria, and lowering the risk of cardiovascular events. Landmark trials like DAPA-CKD and EMPA-KIDNEY highlight their efficacy in both diabetic and non-diabetic CKD populations.
In clinical practice, the integration of SGLT2 inhibitors has shifted the paradigm of CKD care toward early intervention and comprehensive risk reduction. Beyond renal benefits, their safety profile and ability to mitigate heart failure risks make them a preferred choice for multimorbidity management in CKD patients. Ongoing research aims to expand their application and refine treatment strategies for broader populations.
Therefore, get an overall knowledge Evidence to Practice : State of the art CKD Care with SLGT2- inhibitors. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease
2.
Research uncovers hidden Australian skin cancer epidemic
3.
Immunotherapy and targeted radiation shrink liver tumors, enabling surgery
4.
In Higher-Risk MDS, CMML, All-Oral Therapy Has Promise.
5.
The American College of Physicians updated its recommendations for colorectal cancer screening.
1.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
2.
The Role of Alanine Aminotransferase in Liver Health and Disease
3.
Unveiling Canine Blood Clots Over Time: A Look at Low-Field MRI's Diagnostic Potential
4.
Breaking Down the Different Types of Lymphoma: What You Need to Know
5.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
2.
Efficient Management of First line ALK-rearranged NSCLC - Part V
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
4.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation